Clean Science and Technology Limited — PPTs, 17-07-2025: Investor Presentation

**1. Financial Highlights:**

FY2025 consolidated revenue hit a record 950 Cr with ~41% EBITDA margin. Q1 FY2026 consolidated revenue was 243 Cr, achieving 70 Cr PAT and 41.7% consolidated EBITDA margin, driven by HALS sales.

**2. Strategic Initiatives & Growth Drivers:**

Greenfield capex progresses for new, high-value products. R&D (90 scientists) optimizes catalyst systems and expands performance chemical offerings, emphasizing clean chemistry and sustainability.

**3. Business Developments:**

Newer launches contributed over 25% of FY2025 revenue. HALS sales volume soared 3.3x, making the company one of few globally fully backward-integrated. Water trials for Performance Chemical 1 begin August; Performance Chemical 2 capex on track.

**4. Market Position & Competitive Advantage:**

A specialty chemical leader, holding global #1/2 positions for several in-house developed products (e.g., MEHQ, HALS). Serves 500+ global customers, debt-free, and differentiates via innovative, sustainable catalytic processes.

**5. Investor Implications:**

Solid financials, strategic high-value product investments, and expanding HALS market share signal positive growth potential. Ongoing R&D and sustainability focus support long-term value.